This phase I multicenter study was aimed at assessing the feasibility and safety of intravenous administration of third party bone marrow-derived mesenchymal stromal cells (MSC) expanded in platelet lysate in 40 patients (15 children and 25 adults), experiencing steroid-resistant grade II to IV graft-versus-host disease (GVHD). Patients received a median of 3 MSC infusions after having failed conventional immunosuppressive therapy. A median cell dose of 1.5 × 10(6)/kg per infusion was administered. No acute toxicity was reported. Overall, 86 adverse events and serious adverse events were reported in the study, most of which (72.1%) were of infectious nature. Overall response rate, measured at 28 days after the last MSC injection, was 67.5%, with 27.5% complete response. The latter was significantly more frequent in patients exhibiting grade II GVHD as compared with higher grades (61.5% versus 11.1%, P = .002) and was borderline significant in children as compared with adults (46.7 versus 16.0%, P = .065). Overall survival at 1 and 2 years from the first MSC administration was 50.0% and 38.6%, with a median survival time of 1.1 years. In conclusion, MSC can be safely administered on top of conventional immunosuppression for steroid resistant GVHD treatment. Eudract Number 2008-007869-23, NCT01764100.
Human bone marrow mesenchymal stromal cells (BM-MSC) represent one of the most investigated "advanced therapeutic medicinal products".1 Recent safety concerns have focused attention on the possible malignant transformation due to mutations acquired during their large-scale in vitro expansion.2 Indeed, spontaneous oncogenic transformation has been described for murine MSC 3 although not for human cells, 4,5 with the exception of a few studies, 6which were subsequently retracted when it was realized that this was due to cross-contamination by a tumor cell line. 7,8 One single report has described the in vitro outgrowth of a transformed subpopulation from a normal BM sample.9 Furthermore, genetic aberrations of MSC have been very occasionally observed after long-term cultures 4,10,11 but interpreted to be related to senescence. 5In order to investigate the frequency of cytogenetic alterations in a broad "collection" of clinical-grade BM-MSC products, we performed cytogenetic analysis of 92 preparations expanded under Good Manufacturing Practice conditions.12 More precisely, 67 expansions were performed from 33 healthy donors, 4 β−thalassemia patients and 21 multiple sclerosis patients (Table 1). MSC were expanded from BM washouts or aspirates using human platelet lysate as previously described.12,13 Metaphases were prepared according to standard procedures 12 and analyzed by QFQ-banding. At least 20 metaphases per sample were analyzed. Karyotype was described according to the International System for Human Cytogenetic Nomenclature. Furthermore, p53 gene mutations were analyzed by deep sequencing of exons 5 to 11.Chromosomal abnormalities were detected in 17 of 86 expansions (19.8%). In all cases, the genetic lesions were spontaneous abnormalities.2 In 14 cases they were nonclonal: in 8 they involved one metaphase (MSC46, MSC70, MSC74, MSC79, MSC82, MSC87, MSC121, MSC126); in 5 two different chromosome abnormalities in two metaphases (MSC52, MSC55, MSC66 MSC100, MSC116). Only in one case were three different alterations in three metaphases found (MSC80). "Clonal chromosome changes" 2 were detected in 3 cases: in MSC114 monosomy of chromosome X was found in three metaphases, while in MSC119 and MSC122 inversion of chromosome 1 and a translocation involving chromosomes 9 and 4, respectively, were found in two metaphases. We also examined the results of multiple expansions from the same donors. Chromosomal anomalies were observed for 7 out of 13 donors (ns. 18, 20, 23, 32, 37, 50, 63), but these lesions were not recurrent and present only in some of the expansions performed. This suggests that chromosome aberrations do not associate with specific donors. In 6 cases, cytogenetic evaluation could not be performed on the final fresh P2 products due to lack of metaphases (Table 1) but in 5 of these the analyses could be repeated using a frozen P2 aliquot and in 4 cases karyotypes were normal. Similarly, when spontaneous and non-clonal abnormalities were detected, the karyotype analysis was repeated using a frozen P2 aliqu...
The online version of this article has a supplementary appendix. BackgroundThe histone deacetylase inhibitor ITF2357 has potent cytotoxic activity in multiple myeloma in vitro and has entered clinical trials for this disease. Design and MethodsIn order to gain an overall view of the activity of ITF2357 and identify specific pathways that may be modulated by the drug, we performed gene expression profiling of the KMS18 multiple myeloma cell line treated with the drug. The modulation of several genes and their biological consequence were verified in a panel of multiple myeloma cell lines and cells freshly isolated from patients by using polymerase chain reaction analysis and western blotting. ResultsOut of 38,500 human genes, we identified 140 and 574 up-regulated genes and 102 and 556 down-modulated genes at 2 and 6 h, respectively, with a significant presence of genes related to transcription regulation at 2 h and to cell cycling and apoptosis at 6 h. Several of the identified genes are particularly relevant to the biology of multiple myeloma and it was confirmed that ITF2357 also modulated their encoded proteins in different multiple myeloma cell lines. In particular, ITF2357 down-modulated the interleukin-6 receptor α (CD126) transcript and protein in both cell lines and freshly isolated patients' cells, whereas it did not significantly modify interleukin-6 receptor β (CD130) expression. The decrease in CD126 expression was accompanied by decreased signaling by interleukin-6 receptor, as measured by STAT3 phosphorylation in the presence and absence of interleukin-6. Finally, the drug significantly down-modulated the MIRHG1 transcript and its associated microRNA, miR-19a and miR-19b, known to have oncogenic activity in multiple myeloma. ConclusionsITF2357 inhibits several signaling pathways involved in myeloma cell growth and survival.Key words: pleiotropic anti-myeloma, ITF2357, interleukin-6 receptor, miR-19a, miR-19b. -19a and miR-19b. Haematologica. 2010; 95:260-269. doi:10.3324/haematol.2009 This is an open-access paper.Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.